Cost-effectiveness of carbapenem-resistant Enterobacteriaceae (CRE) surveillance in Maryland.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
09 2022
Historique:
pubmed: 23 10 2021
medline: 20 9 2022
entrez: 22 10 2021
Statut: ppublish

Résumé

We analyzed the efficacy, cost, and cost-effectiveness of predictive decision-support systems based on surveillance interventions to reduce the spread of carbapenem-resistant Enterobacteriaceae (CRE). We developed a computational model that included patient movement between acute-care hospitals (ACHs), long-term care facilities (LTCFs), and communities to simulate the transmission and epidemiology of CRE. A comparative cost-effectiveness analysis was conducted on several surveillance strategies to detect asymptomatic CRE colonization, which included screening in ICUs at select or all hospitals, a statewide registry, or a combination of hospital screening and a statewide registry. We investigated 51 ACHs, 222 LTCFs, and skilled nursing facilities, and 464 ZIP codes in the state of Maryland. The model was informed using 2013-2016 patient-mix data from the Maryland Health Services Cost Review Commission. This model included all patients that were admitted to an ACH. On average, the implementation of a statewide CRE registry reduced annual CRE infections by 6.3% (18.8 cases). Policies of screening in select or all ICUs without a statewide registry had no significant impact on the incidence of CRE infections. Predictive algorithms, which identified any high-risk patient, reduced colonization incidence by an average of 1.2% (3.7 cases) without a registry and 7.0% (20.9 cases) with a registry. Implementation of the registry was estimated to save $572,000 statewide in averted infections per year. Although hospital-level surveillance provided minimal reductions in CRE infections, regional coordination with a statewide registry of CRE patients reduced infections and was cost-effective.

Identifiants

pubmed: 34674791
pii: S0899823X21003615
doi: 10.1017/ice.2021.361
pmc: PMC9023597
mid: NIHMS1752629
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1162-1170

Subventions

Organisme : NCEZID CDC HHS
ID : U01 CK000536
Pays : United States
Organisme : NCEZID CDC HHS
ID : U01 CK000589
Pays : United States

Références

Am J Epidemiol. 2016 Mar 1;183(5):471-9
pubmed: 26861238
Virulence. 2017 May 19;8(4):417-426
pubmed: 27813699
Open Forum Infect Dis. 2020 Feb 15;7(3):ofaa056
pubmed: 32166095
Am J Epidemiol. 1997 Jun 15;145(12):1127-37
pubmed: 9199543
Infect Control Hosp Epidemiol. 2014 Apr;35(4):440-2
pubmed: 24602954
N Engl J Med. 2001 May 10;344(19):1427-33
pubmed: 11346807
Am J Infect Control. 2014 Jun;42(6):612-20
pubmed: 24837111
Am J Infect Control. 2017 Nov 1;45(11):1177-1182
pubmed: 28757088
Infect Control Hosp Epidemiol. 2006 Mar;27(3):228-32
pubmed: 16532408
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
Infect Control Hosp Epidemiol. 2015 Oct;36(10):1163-72
pubmed: 26138329
J Clin Microbiol. 2005 Apr;43(4):2034; author reply 2034-5
pubmed: 15815056
Eur J Clin Microbiol Infect Dis. 1999 Jul;18(7):461-6
pubmed: 10482021
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11157-62
pubmed: 16055564
Cleve Clin J Med. 2013 Apr;80(4):225-33
pubmed: 23547093
Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):782-6
pubmed: 12461587
Clin Infect Dis. 2019 Feb 15;68(5):873-884
pubmed: 30475989
JAMA. 2015 Oct 13;314(14):1479-87
pubmed: 26436831
Antimicrob Agents Chemother. 2008 Mar;52(3):1028-33
pubmed: 18086836
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1491-1493
pubmed: 30269700
Clin Infect Dis. 2021 Feb 1;72(3):431-437
pubmed: 31970393
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
Clin Infect Dis. 2020 Feb 14;70(5):843-849
pubmed: 31070719
Emerg Infect Dis. 2015 Oct;21(10):1725-32
pubmed: 26402744
Lancet. 2010 Dec 4;376(9756):1910-5
pubmed: 21122910
Science. 2000 Jan 28;287(5453):650-4
pubmed: 10649998
J Antimicrob Chemother. 2007 Nov;60(5):1124-30
pubmed: 17884829
Am J Gastroenterol. 2015 Dec;110(12):1666-74
pubmed: 26526083
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150
pubmed: 30046639
Infect Control Hosp Epidemiol. 2012 Aug;33(8):817-30
pubmed: 22759550
Clin Infect Dis. 2011 Apr 1;52(7):848-55
pubmed: 21317398
Clin Infect Dis. 2015 Apr 15;60(8):1153-61
pubmed: 25537877
Clin Microbiol Infect. 2017 Jan;23(1):48.e9-48.e16
pubmed: 27642178
Arch Intern Med. 2002 Jan 28;162(2):185-90
pubmed: 11802752

Auteurs

Gary Lin (G)

Center for Disease Dynamics, Economics & Policy, Silver Spring, Maryland, United States.

Katie K Tseng (KK)

Center for Disease Dynamics, Economics & Policy, Silver Spring, Maryland, United States.

Oliver Gatalo (O)

Center for Disease Dynamics, Economics & Policy, Silver Spring, Maryland, United States.

Diego A Martinez (DA)

School of Industrial Engineering, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.

Jeremiah S Hinson (JS)

Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland, United States.

Aaron M Milstone (AM)

Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, United States.
Department of Hospital Epidemiology and Infection Control, The Johns Hopkins Hospital, Baltimore, Maryland, United States.

Scott Levin (S)

Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland, United States.

Eili Klein (E)

Center for Disease Dynamics, Economics & Policy, Silver Spring, Maryland, United States.
Department of Emergency Medicine, Johns Hopkins University, Baltimore, Maryland, United States.
Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH